Inveksi Human Papilloma Virus (HPV) dan Pencegahannya pada Remaja dan Dewasa Muda
DOI:
https://doi.org/10.31957/jbp.564Abstract
Human papillomavirus (HPV) is a significant source of morbidity and mortality worldwide. The primary risk factors for aquiring HPV are generally associated with sexual activity. Â Evidence suggest that condoms provide some protection against infection and disease progression, but any genital contact is sufficient for HPV transmission. Â Having more than one sexual partner often result in HPV infection. Â All sexually active adolescents are at high risk for aquiring HPV. Â Persistent infection with high-risk HPV types (e.g HPV 16 or 18) is considered necessary for the development cervical cancer. Â Most infection are asymptomatic and are efficiently cleared by he immune system. Â The lesions that caused by HPV can regress in adolescent and young adult women. Â A small percentage of adolescents will develop precancerous lesions that may progress to invasive cervical cancer. Â Adolescents should be given appropriate education about HPV and the dangers associated with infection. Â Vaccination for HPV infection should be given for presexually active children and adolescents.
Key words: human papilloma virus, adolescent, cervical cancer, vaccination.Â
Downloads
References
Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in cohort of closely followed adolescent women. J Infect Dis 2005 191:182-92.
Cates WJ. Estimates of the incidence and prevalence of sexually transmitted disease in the United States. American Social Health Association Panel. Sex Transm Dis 1999; 26:S2-7.
Harper DM. Why am I scared of HPV? CAA Cancer J Clin 2004;54:245-7.
Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus : randomized clinical trial. Intl J Cancer 2003;107:811-6.
Ley C, Bauer HM, Reingold A, et al. Determinants of genital human papillomavirus infection in young woman. J Natl Cancer Inst 1991;83:997-1003.
Mc Caffery K, Waller J, Forrest S, et al. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG 2004;111:1437-443.
Moscicki AB, Hills N, Shiboski S, et al. Risk for incident human papillomavirus infection and low grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62.
Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003;31:14-9.
Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001;8:209-20.
Smith JS, Bosetti C, Munoz N, et al. Chlamydia trachomatis and invasive cervical cancer: pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004;111:431-9.
Solomon D, Davey D, Kurman, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
Stanley M. HPV vaccines. Best Pract. Res. Clin. Obstet. Gynaecol. 2006;20:279-93.
Stewart B, Kleihues P, eds. World Health Organization World Cancer Report. Lyons, France. World Health Organization, 2003.
Weinstock H, Berman S, Cates WJ. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004;36:6-10.
WHO. WHO position on HPV vaccines. Vaccine. 2009;27:7236-37.
Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factor in a cohort female university students. Am J Epidemiol 2003;157:218-26.
